Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 87

1.

Inhibition of stromal CXCR4 impairs development of lung metastases.

D'Alterio C, Barbieri A, Portella L, Palma G, Polimeno M, Riccio A, IeranĂ² C, Franco R, Scognamiglio G, Bryce J, Luciano A, Rea D, Arra C, Scala S.

Cancer Immunol Immunother. 2012 Oct;61(10):1713-20. Epub 2012 Mar 8.

2.

Preclinical development of a novel class of CXCR4 antagonist impairing solid tumors growth and metastases.

Portella L, Vitale R, De Luca S, D'Alterio C, IeranĂ² C, Napolitano M, Riccio A, Polimeno MN, Monfregola L, Barbieri A, Luciano A, Ciarmiello A, Arra C, Castello G, Amodeo P, Scala S.

PLoS One. 2013 Sep 13;8(9):e74548. doi: 10.1371/journal.pone.0074548. eCollection 2013.

3.

Sensitization of B16 tumor cells with a CXCR4 antagonist increases the efficacy of immunotherapy for established lung metastases.

Lee CH, Kakinuma T, Wang J, Zhang H, Palmer DC, Restifo NP, Hwang ST.

Mol Cancer Ther. 2006 Oct;5(10):2592-9.

4.

CXCR4 signaling regulates metastasis of chemoresistant melanoma cells by a lymphatic metastatic niche.

Kim M, Koh YJ, Kim KE, Koh BI, Nam DH, Alitalo K, Kim I, Koh GY.

Cancer Res. 2010 Dec 15;70(24):10411-21. doi: 10.1158/0008-5472.CAN-10-2591. Epub 2010 Nov 5.

5.

Development of a unique small molecule modulator of CXCR4.

Liang Z, Zhan W, Zhu A, Yoon Y, Lin S, Sasaki M, Klapproth JM, Yang H, Grossniklaus HE, Xu J, Rojas M, Voll RJ, Goodman MM, Arrendale RF, Liu J, Yun CC, Snyder JP, Liotta DC, Shim H.

PLoS One. 2012;7(4):e34038. doi: 10.1371/journal.pone.0034038. Epub 2012 Apr 2.

6.
7.

Expression of CXC chemokine receptor-4 enhances the pulmonary metastatic potential of murine B16 melanoma cells.

Murakami T, Maki W, Cardones AR, Fang H, Tun Kyi A, Nestle FO, Hwang ST.

Cancer Res. 2002 Dec 15;62(24):7328-34.

8.

Potential of CXCR4 antagonists for the treatment of metastatic lung cancer.

Burger JA, Stewart DJ, Wald O, Peled A.

Expert Rev Anticancer Ther. 2011 Apr;11(4):621-30. doi: 10.1586/era.11.11. Review.

PMID:
21504328
9.

COX-2 and prostaglandin EP3/EP4 signaling regulate the tumor stromal proangiogenic microenvironment via CXCL12-CXCR4 chemokine systems.

Katoh H, Hosono K, Ito Y, Suzuki T, Ogawa Y, Kubo H, Kamata H, Mishima T, Tamaki H, Sakagami H, Sugimoto Y, Narumiya S, Watanabe M, Majima M.

Am J Pathol. 2010 Mar;176(3):1469-83. doi: 10.2353/ajpath.2010.090607. Epub 2010 Jan 28.

10.

CXCR4 chemokine receptor antagonists: perspectives in SCLC.

Burger JA, Stewart DJ.

Expert Opin Investig Drugs. 2009 Apr;18(4):481-90. doi: 10.1517/13543780902804249 . Review.

PMID:
19335276
11.

Pro-inflammatory properties of stromal cell-derived factor-1 (CXCL12) in collagen-induced arthritis.

De Klerck B, Geboes L, Hatse S, Kelchtermans H, Meyvis Y, Vermeire K, Bridger G, Billiau A, Schols D, Matthys P.

Arthritis Res Ther. 2005;7(6):R1208-20. Epub 2005 Aug 25.

12.

Inhibitory effect of CXC chemokine receptor 4 antagonist AMD3100 on bleomycin induced murine pulmonary fibrosis.

Song JS, Kang CM, Kang HH, Yoon HK, Kim YK, Kim KH, Moon HS, Park SH.

Exp Mol Med. 2010 Jun 30;42(6):465-72.

13.

C-X-C receptor type 4 promotes metastasis by activating p38 mitogen-activated protein kinase in myeloid differentiation antigen (Gr-1)-positive cells.

Hiratsuka S, Duda DG, Huang Y, Goel S, Sugiyama T, Nagasawa T, Fukumura D, Jain RK.

Proc Natl Acad Sci U S A. 2011 Jan 4;108(1):302-7. doi: 10.1073/pnas.1016917108. Epub 2010 Dec 20.

14.

Plerixafor inhibits chemotaxis toward SDF-1 and CXCR4-mediated stroma contact in a dose-dependent manner resulting in increased susceptibility of BCR-ABL+ cell to Imatinib and Nilotinib.

Dillmann F, Veldwijk MR, Laufs S, Sperandio M, Calandra G, Wenz F, Zeller J, Fruehauf S.

Leuk Lymphoma. 2009 Oct;50(10):1676-86. doi: 10.1080/10428190903150847.

PMID:
19657955
15.

Inhibition of the CXCR4/CXCL12 chemokine pathway reduces the development of murine pulmonary metastases.

Kim SY, Lee CH, Midura BV, Yeung C, Mendoza A, Hong SH, Ren L, Wong D, Korz W, Merzouk A, Salari H, Zhang H, Hwang ST, Khanna C, Helman LJ.

Clin Exp Metastasis. 2008;25(3):201-11. Epub 2007 Dec 11.

16.

CXCR4 antagonists: targeting the microenvironment in leukemia and other cancers.

Burger JA, Peled A.

Leukemia. 2009 Jan;23(1):43-52. doi: 10.1038/leu.2008.299. Epub 2008 Nov 6. Review.

PMID:
18987663
17.

Involvement of chemokine receptor 4/stromal cell-derived factor 1 system during osteosarcoma tumor progression.

Perissinotto E, Cavalloni G, Leone F, Fonsato V, Mitola S, Grignani G, Surrenti N, Sangiolo D, Bussolino F, Piacibello W, Aglietta M.

Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):490-7.

18.

C-C chemokine receptor 5 on stromal cells promotes pulmonary metastasis.

van Deventer HW, O'Connor W Jr, Brickey WJ, Aris RM, Ting JP, Serody JS.

Cancer Res. 2005 Apr 15;65(8):3374-9.

19.

A role of CXC chemokine ligand 12/stromal cell-derived factor-1/pre-B cell growth stimulating factor and its receptor CXCR4 in fetal and adult T cell development in vivo.

Ara T, Itoi M, Kawabata K, Egawa T, Tokoyoda K, Sugiyama T, Fujii N, Amagai T, Nagasawa T.

J Immunol. 2003 May 1;170(9):4649-55.

20.

Combination of vessel-targeting agents and fractionated radiation therapy: the role of the SDF-1/CXCR4 pathway.

Chen FH, Fu SY, Yang YC, Wang CC, Chiang CS, Hong JH.

Int J Radiat Oncol Biol Phys. 2013 Jul 15;86(4):777-84. doi: 10.1016/j.ijrobp.2013.02.036. Epub 2013 Apr 16.

PMID:
23601898
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk